This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Chronic Lymphocytic Leukemia
and you are
over 18
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine whether on course (6 cycles) of consolidation therapy with Revlimid can shrink or slow the growth of Chronic Lymphocytic Leukemia (CLL) in the bone marrow.

Provided treatments

  • Drug: Lenalidomide
Tris trial is registered with FDA with number: NCT01600053. The sponsor of the trial is Thomas Kipps and it is looking for 11 volunteers for the current phase.
Official trial title:
A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)